

**Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma:
Further analyses from the LUME-Lung 1 study**

[D. Heigener](#), [M. Gottfried](#), [J. Bennouna](#), [I. Bondarenko](#), [J-Y. Douillard](#), [M. Krzakowski](#), [A. Mellempgaard](#), [S. Novello](#), [S. Orlov](#), [Y.J. Summers](#)

Ann Oncol (2016) 27 (suppl_6): 1276P.

DOI: <https://doi.org/10.1093/annonc/mdw383.76>

Published: 11 October 2016

Background: NIN is a triple angiokinase inhibitor approved in the EU in combination with DOC for the treatment of adenocarcinoma non-small cell lung cancer patients after first-line therapy (FLT). A continuous linear correlation between overall survival (OS) benefit with NIN and the predictive marker “time from start of FLT” (TSFLT) has been observed in adenocarcinoma patients.

Methods: First, analyses were conducted of European adenocarcinoma patients, who comprise the majority of the population from the Phase III LUME-Lung 1 trial comparing NIN/DOC with placebo (PLA)/DOC (NCT00805194). Second, in order to further characterise time from FLT, analyses were conducted in adenocarcinoma populations defined by the dichotomisation at appropriate cut-points of TSFLT or progressive disease (PD) as best response to FLT. Analyses based on “time from end...

Issue Section:

[Submitted abstracts](#)

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

You do not currently have access to this article.